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A Ab bs st tr ra ac ct t
B Ba ac ck kg gr ro ou un nd d: :    Insulin and insulin-like growth factors (IGFs) signal through a highly conserved
pathway and control growth and metabolism in both vertebrates and invertebrates. In mammals,
insulin-like growth factor binding proteins (IGFBPs) bind IGFs with high affinity and modulate
their mitogenic, anti-apoptotic and metabolic actions, but no functional homologs have been
identified in invertebrates so far.
R Re es su ul lt ts s: :   Here, we show that the secreted Imaginal morphogenesis protein-Late 2 (Imp-L2) binds
Drosophila insulin-like peptide 2 (Dilp2) and inhibits growth non-autonomously. Whereas over-
expressing Imp-L2 strongly reduces size, loss of Imp-L2 function results in an increased body
size. Imp-L2 is both necessary and sufficient to compensate Dilp2-induced hyperinsulinemia in
vivo. Under starvation conditions, Imp-L2 is essential for proper dampening of insulin signaling
and larval survival.
C Co on nc cl lu us si io on ns s: :    Imp-L2, the first functionally characterized insulin-binding protein in
invertebrates, serves as a nutritionally controlled suppressor of insulin-mediated growth in
Drosophila. Given that Imp-L2 and the human tumor suppressor IGFBP-7 show sequence
homology in their carboxy-terminal immunoglobulin-like domains, we suggest that their
common precursor was an ancestral insulin-binding protein.
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Insulin/insulin-like growth factor (IGF) signaling (termed
IIS) is involved in the regulation of growth, metabolism,
reproduction and longevity in mammals [1-3]. The
activity of IIS is regulated at multiple levels, both
extracellularly and intracellularly: the production and
release of the ligands is regulated, and normally IGFs are
also bound and transported by IGFBPs in extracellular
cavities of vertebrates [4]. IGFBPs not only prolong the
half-lives of IGFs, but they also modulate their
availability and activity [5]. Besides the classical IGFBPs
(IGFBP1-6), a related protein called IGFBP-7 (or IGFBP-
rP1, Mac25, TAF, AGM or PSF) has been identified as an
insulin-binding protein [6]. Although the reported
binding of IGFBP-7 to insulin awaits confirmation [7,8],
it can compete with insulin for binding to the insulin
receptor (InR) and inhibit the autophosphorylation of
InR [6]. Furthermore, IGFBP-7 is suspected to be a tumor
suppressor in a variety of human organs, including breast,
lung and colon [6,9-13]. A recent publication
demonstrates that IGFBP-7 induces senescence and
apoptosis in an autocrine/paracrine manner in human
primary fibroblasts in response to an activated BRAF
oncogene [14].
IIS is astonishingly well conserved in invertebrates. In
Drosophila, IIS acts primarily to promote cellular
growth, but it also affects metabolism, fertility and
longevity [15,16]. Seven insulin-like peptides (Dilp1-7)
homologous to vertebrate insulin and IGF-I have been
identified as putative ligands of the Drosophila insulin
receptor (dInR) [17]. These Dilps are expressed in a
spatially and temporally controlled pattern, including
expression in median neurosecretory cells (m-NSCs) of
both brain hemispheres. The m-NSCs have axon
terminals in the larval endocrine gland and on the
aorta, where the Dilps are secreted into the hemolymph
[17-19]. Ablation of the m-NSCs causes a
developmental delay, growth retardation and elevated
carbohydrate levels in the larval hemolymph [18,19],
reminiscent of the phenotypes of starved or IIS-
impaired flies.
The  Drosophila genome does not encode an obvious
homolog of the IGFBPs. Furthermore, genetic analyses of
IIS in Drosophila and  Caenorhabditis elegans have not
revealed a functional insulin-binding protein so far.
Here, we report the identification of the secreted protein
Imp-L2 as a binding partner of Dilp2. Imp-L2 is not
essential under standard conditions, but flies lacking
Imp-L2 function are larger. Under adverse nutritional
conditions, Imp-L2 is upregulated in the fat body and
represses IIS activity in the entire organism, allowing the
animal to endure periods of starvation.
R Re es su ul lt ts s
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We reasoned that the overexpression of a Dilp-binding
protein that impinges on the ligand-receptor interaction
should counteract the effects of receptor overexpression.
dInR overexpression during eye development (by means of a
GMR-Gal4 strain, in which the Gal4 protein is overexpressed
in photoreceptor neurons, and a UAS-dInR, which expresses
dInR when activated by Gal4) results in hyperplasia of the
eyes, a phenotype that is sensitive to the levels of the Dilps
[17]. A collection of enhancer-promoter (EP) elements,
which allow the overexpression of nearby genes (F.W., W.B.,
H.S., D. Nellen, K. Basler and E.H., unpublished work), was
screened for suppressors of the dInR-induced hyperplasia
(Figure 1a). A strong suppressor (EP5.66, Figure 1b) carried
an EP element 8.5 kb upstream of the Imp-L2 coding
sequence (Figure 1f). Two different UAS transgenes, both
containing the Imp-L2 coding sequence but varying in
strength, confirmed that the suppression was caused by
Imp-L2. Whereas the weaker UAS-Imp-L2  (containing 5’
sequences with three upstream open reading frames) only
partially suppressed the dInR-induced overgrowth (Figure 1c),
UAS-strong.Imp-L2 (UAS-s.Imp-L2, lacking the 5’ sequences)
completely reversed the phenotype (Figure 1d). In addition,
a point mutation in the Imp-L2 coding sequence (see below)
abolished the suppressive effect of EP5.66 (Figure 1e). Imp-
L2 is therefore a potent antagonist of dInR-induced growth.
Imp-L2 has previously been shown to be upregulated 8-10
hours after ecdysone treatment [20,21]. It encodes a secreted
member of the immunoglobulin (Ig) superfamily contain-
ing two Ig C2-like domains. Whereas several orthologs of
Imp-L2 are present in invertebrates such as arthropods and
nematodes, the homology in vertebrates is confined to the
second Ig C2-like domain, which is homologous to the
carboxyl terminus of human IGFBP-7 (Figure 1g). The
carboxy-terminal part of IGFBP-7 differs considerably from
the other IGFBPs, possibly accounting for the affinity of
IGFBP-7 for insulin [6]. Interestingly, Imp-L2 has been
shown to bind human insulin, IGF-I, IGF-II and proinsulin,
and its homolog in the moth Spodoptera frugiperda, Sf-IBP,
can inhibit insulin signaling through the insulin receptor [22].
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To further assess the function of Imp-L2 as a secreted
inhibitor of insulin signaling, we ectopically expressed Imp-
L2 using various Gal4 drivers. Strong ubiquitous over-
expression of Imp-L2 by Act-Gal4 led to lethality with both
UAS transgenes. Whereas driving UAS-s.Imp-L2 by the
weaker ubiquitous arm-Gal4 driver also resulted in lethality,
driving UAS-Imp-L2 generated flies that were decreased in
size and weight (-15% in males and -29% in females, data
10.2 Journal of Biology 2008, Volume 7, Article 10 Honegger et al. http://jbiol.com/content/7/3/10
Journal of Biology 2008, 7 7: :10not shown) but eclosed at the expected ratio and had wild-
type appearance. By generating clones of cells that over-
express  Imp-L2, we confirmed that cell specification and
patterning were normal in Imp-L2-overexpressing ommatidia
(Figure 2a). However, a reduction of cell size was observed
in the clones. This reduction seemed to be non-autonomous
because wild-type ommatidia close to the clone were also
reduced in size. Given the convex nature of the eye we were
unable to quantify the effects of Imp-L2 overexpression on
more distantly located ommatidia. Eye-specific overexpression
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Imp-L2 overexpression suppresses dInR-induced growth. ( (a a- -e e) )   Scanning electron micrographs of compound eyes. All flies (females) carry the GMR-
Gal4 and UAS-dInRwt transgenes. The dInr-dependent big eye phenotype (a) is suppressed by EP5.66 (b). UAS-Imp-L2 (c) and the stronger UAS-
s.Imp-L2 (d) also suppress, but EP5.66 driving the mutant Imp-L2MG2 allele can no longer suppress the dInR overexpression phenotype (e). ( (f f) )
Genomic organization of the Imp-L2 locus. The mutant alleles and P-element insertions used in this study are indicated. MG2 marks the point
mutation in the EMS allele Imp-L2MG2 that generates a premature stop codon. ( (g g) ) Alignment of Imp-L2, its orthologs in invertebrates and the putative
human ortholog IGFBP-7. Black and gray boxes indicate amino acid identity and similarity, respectively. The triangle marks the premature stop codon
in Imp-L2MG2. Asterisks mark the cysteines forming the two disulfide bridges. The gray bars indicate the Ig domains. Dm, Drosophila melanogaster
Imp-L2; Ag, Anopheles gambiae CP2953; Sf, Spodoptera frugiperda IBP; Ce, Caenorhabditis elegans zig-4; Hs, Homo sapiens IGFBP-7.
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* *of both UAS-Imp-L2 and UAS-s.Imp-L2 by GMR-Gal4 led to
a strong reduction in eye size (data not shown). Whereas
the GMR-Gal4, UAS-Imp-L2 flies were of normal size, body
weight was reduced by 38.3% and development was
delayed by one day in GMR-Gal4, UAS-s.Imp-L2 male flies
(Figure 2b). Next, we used the ppl-Gal4 driver to over-
express Imp-L2 in the fat body, a tissue that can be expected
to produce and secrete Imp-L2 more efficiently than the
eye. Driving UAS-s.Imp-L2 by ppl-Gal4 was lethal, whereas
ppl-Gal4, UAS-Imp-L2 flies showed a pronounced reduction
in body size (Figure 2c) and were delayed by 2 days. Both
the size decrease and the developmental delay are
characteristic phenotypes of reduced IIS such as in chico
mutants [23], supporting the hypothesis that Imp-L2 acts
as a secreted negative regulator of this pathway.
Next, we assessed the effect of Imp-L2 overexpression on
phosphatidylinositol(3,4,5)trisphosphate (PIP3) levels using
a green fluorescent protein-pleckstrin homology domain
fusion protein (tGPH) that specifically binds PIP3 and
serves as a reporter for PIP3 levels in vivo [24]. The amount
of membrane-bound tGPH reflects signaling activity in the
phosphoinositide 3-kinase/protein kinase B (PI 3-kinase/
PKB) pathway. Overexpression of dInR resulted in a severe
increase of membrane PIP3 levels (Additional data file 1,
Figure S1A,B). Co-overexpression of Imp-L2 together with dInR
reduced the PIP3 levels (Additional data file 1, Figure S1D),
similar to the effect caused by PTEN (Additional data file 1,
Figure S1C), a negative regulator of IIS. Therefore, Imp-L2
inhibits PI 3-kinase/PKB signaling upstream of PIP3, without
affecting dInR levels (Additional data file 1, Figure S1B’,D’).
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Imp-L2 controls body and organ size. ( (a a) )   Tangential section through an adult eye containing an Imp-L2 overexpression clone marked by the lack of
red pigment. Within the clone, the size of the ommatidia is reduced. Wild-type ommatidia close to the clone are also smaller (compare black circled
areas). ( (b b) )   Eye-specific overexpression of UAS-s.Imp-L2 reduces male body weight (-38.3%, P = 7 x 10-42). ( (c c) )   Overexpression of UAS-Imp-L2 by ppl-
Gal4 results in a 56.1% weight reduction in male flies, whereas ppl-Gal4 driven expression of UAS-s.Imp-L2 results in lethality (†). P = 3 x 10-47. ( (d d) )
Loss of Imp-L2 function increases body size in males (top) and females (bottom). ( (e e) ) Analyses of male and female weights. Wing area, cell number
and cell size were assessed in female adult wings. GR indicates Imp-L2 genomic rescue construct. P-values are indicated by numbers as follows: 1, 2 x
10-33; 2, 8 x 10-18; 3, 9 x 10-16; 4, 6 x 10-7; 5, 3 x 10-46; 6, 1 x 10-24; 7, 8 x 10-31; 8, 2 x 10-7; 9, 4 x 10-4; 10, 4 x 10-7; 11, 3 x 10-7; 12, 1x 10-4.
Genotypes: ‘control’ y, w/w; ‘Imp-L2-/-’ y, w; Imp-L2Def42/Imp-L2Def20; ‘Imp-L2+/-’ for the weight analysis (e) y, w; Imp-L2 Def20/+; ‘Imp-L2+/-’ for the
wing analysis (e) y, w; Imp-L2 Def42/+; ‘Imp-L2-/-, GR’ y, w; Imp-L2 Def42/Imp-L2 Def20, GR-57; ‘Imp-L2+/-, GR’ y, w; Imp-L2 Def20, GR-57/+. P-values were
determined using unpaired Student’s t-test against the control except in (4) where the weight of IMP-L2+/- was compared to IMP-L2+/-, GR. n = 40 for
the weight analysis in (b,c,e); n = 12 for the wing analysis in (e). Error bars represent s.d.
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We used two strategies to generate loss-of-function
mutations in Imp-L2. First, we performed an ethylmethane-
sulfonate (EMS) reversion screen in which we selected
mutated chromosomes carrying EP5.66 that no longer
suppressed the dInR overexpression phenotype (Figure 1a).
One allele (Imp-L2MG2) containing a point mutation result-
ing in a premature stop at amino acid 232 was identified in
this way (Figure 1e,f). This truncation destroys the con-
served cysteine bridge of the second Ig domain (Figure 1g).
Overexpression of the truncated Imp-L2 version had no
inhibitory effect on size (Figure 1e), suggesting that
Imp-L2MG2 is a functional null allele.
Second, we generated additional Imp-L2 alleles by
imprecise excision of GE24013 (GenExel), a P-element
located 349 bp upstream of the ATG start codon of the
Imp-L2-RB  transcript (Figure 1f). We obtained Imp-L2
deletions (Def20, Def42) lacking the entire coding
sequence. Heteroallelic combinations of the mutant alleles
increased body size: whereas mutant males showed a 27%
increase in body weight, mutant females were 64% heavier
(Figure 2d,e). Introducing one copy of a genomic rescue
construct (Figure 1f) [25] into homozygous mutant flies
reverted the weight to the level of Imp-L2+/- flies, which
were already heavier (+14% in males, +44% in females,
Figure 2e) than the controls. By measuring the cell density
in the wing, the size increase could be attributed primarily
to an increase in the number of cells, because cell size was
only slightly affected (Figure 2e). Apart from the size
increase, the flies lacking Imp-L2 appeared completely
normal, eclosed with the expected frequency and were not
delayed. Thus, under standard conditions, Imp-L2 loss-of-
function dominantly increases growth by augmenting cell
number without perturbing patterning, developmental
timing or viability.
The weight difference was more pronounced in mutant
females than in males, although the increases in wing
area and cell number were similar (Figure 2e and data
not shown). This differential effect was caused by
enlarged ovaries in Imp-L2 mutant females (data not
shown).
I Im mp p- -L L2 2   b bi in nd ds s   t to o   a an nd d   a an nt ta ag go on ni iz ze es s   D Di il lp p2 2
The facts that Imp-L2 is a secreted protein and that removal
of Imp-L2 function did not rescue either chico or  PI3K
mutant phenotypes (data not shown) are consistent with
the hypothesis that Imp-L2 acts upstream of the intra-
cellular IIS cascade at the level of the ligands. Immuno-
histochemistry in larval tissues revealed that, besides strong
expression in corpora cardiaca (CC) cells (Figure 3a and
Additional data file 1, Figure S2D), Imp-L2 protein was also
weakly expressed in the seven m-NSCs that produce Dilp1,
Dilp2, Dilp3 and Dilp5 (Figure 3b) and project their axons
directly to the subesophageal ganglion, the CC, the aorta
and the heart [19,26]. Thus, Imp-L2 potentially interacts
with some of the Dilps directly at their source. We therefore
tested for genetic interactions of Imp-L2 with the dilp genes.
A deficiency (Df(3L)AC1) uncovering dilp1-5 not only
dominantly suppressed the dInR-mediated big eye
phenotype [17], but also dominantly enhanced the small
eye phenotype caused by eye-specific overexpression of
Imp-L2 (Additional data file 1, Figure S3). dilp2 is the most
potent growth regulator of all dilp  genes [18]. Weak
ubiquitous overexpression of dilp2 by arm-Gal4 caused an
increase in body and organ size [18], and this phenotype
was dominantly enhanced by heterozygosity for Imp-L2
(Figure 3c). In homozygous Imp-L2 mutants, expression of
dilp2 under the control of arm-Gal4 caused lethality,
reminiscent of strong dilp2 expression [18]. Expressing
Imp-L2 and dilp2 individually at high levels in the fat body
also caused lethality, but coexpression resulted in viable
flies of wild-type size (Figure 3d). Thus, Imp-L2 decreases
the sensitivity to high insulin levels and is sufficient to
rescue the lethality resulting from dilp2-induced
hyperinsulinemia.
It has previously been shown that Imp-L2 can bind human
insulin and insulin-related peptides [22]. To address whether
Imp-L2 binds Dilp2, we constructed a Flag-tagged version of
Dilp2, which is functional (data not shown). Using in vitro
translated,  35S-labeled Imp-L2 together with Flag-Dilp2
extracted from stably transfected S2 cells, we could show
that Imp-L2 binds Dilp2 in vitro (Figure 3e). A truncated
form of Imp-L2 lacking a functional second Ig domain (like
that produced by the MG2  allele) failed to bind Dilp2
(Figure 3e).
I Im mp p- -L L2 2   i is s   e es ss se en nt ti ia al l   u un nd de er r   a ad dv ve er rs se e   n nu ut tr ri it ti io on na al l   c co on nd di it ti io on ns s
Despite being a potent inhibitor of Dilp2 action, Imp-L2 is
not essential under standard conditions. Hyperactivation of
the dInR pathway leads to increased accumulation of
nutrients in adipose tissues, precluding them from
circulating and thus resulting in starvation sensitivity at the
organismal level [24]. We therefore tested whether Imp-L2
functions as an inhibitor of IIS under stress conditions. We
exposed wild-type and Imp-L2 mutant early third instar
larvae to various starvation conditions and scored for
survival. Larvae lacking Imp-L2 showed a massive increase in
mortality rate when exposed to 1% glucose or PBS for 24
hours (Figure 4c). To test whether the inability of the
mutant larvae to cope with starvation was due to a failure in
adjusting IIS, we monitored PIP3 levels under these
conditions. Whereas control flies showed a decrease of PIP3
levels when exposed to complete starvation for 4 hours
http://jbiol.com/content/7/3/10 Journal of Biology 2008, Volume 7, Article 10 Honegger et al. 10.5
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that were comparable to those of control larvae reared on
normal food (Figure 4b), suggesting that Imp-L2 is
necessary to adjust IIS under starvation conditions. The
fact that PIP3 levels were also slightly reduced in Imp-L2
mutants upon starvation could be attributed to the
downregulation of dilp3 and  dilp5 at the transcriptional
level [18].
The dampening of IIS upon starvation could be
achieved either by enhanced secretion of stored Imp-
L2 or by an upregulation of Imp-L2 production.
10.6 Journal of Biology 2008, Volume 7, Article 10 Honegger et al. http://jbiol.com/content/7/3/10
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Imp-L2 binds Dilp2 and counteracts its activity. ( (a a, ,b b) ) Antibody staining of larval brains with an Imp-L2 antibody (green). (a) Specific neurons of both
brain hemispheres, the subesophageal ganglion region (gray arrow) and the corpora cardiaca (white arrow) express Imp-L2 protein. The corpora
allata are innervated by Imp-L2 expressing axons. White arrowheads mark the Dilp-producing m-NSCs. (b) In larvae carrying a dilp2-lacZ.nls
transgene, co-staining with β-galactosidase and Imp-L2 antibodies reveals that the seven dilp-expressing m-NSCs also produce low levels of Imp-L2.
( (c c) )   The size increase of arm-Gal4, UAS-dilp2 flies is dominantly enhanced by reducing Imp-L2 levels. In an Imp-L2-/- background, dilp2 overexpression
results in lethality, which can be rescued by a copy of the Imp-L2 genomic rescue construct (GR). ( (d d) ) Overexpression of dilp2 as well as of Imp-L2 at
high levels by ppl-Gal4 causes lethality, whereas concomitant overexpression of dilp2 and Imp-L2 yields flies of wild-type size. The lacZ transgene
was introduced to rule out a dosage effect of the UAS/Gal4-system. ( (e e) )   Imp-L2 binds Dilp2. In-vitro-translated, 35S-labeled wild-type (ImpL2-IVT,
about 32 kDa) or mutant (ImpL2MG2-IVT, about 30 kDa) Imp-L2 (lane 1) was incubated with cell lysates of either non-transfected (lane 3) or stably
transfected S2 cells expressing Flag-Dilp2 (lane 2). Imp-L2 could only be pulled down in the presence of Dilp2. The Imp-L2MG2 mutation abolished
Dilp2 binding. Genotypes in (c): ‘Imp-L2+/-’ Imp-L2Def42/+; ‘Imp-L2-/-’ Imp-L2Def42/Imp-L2Def20; ‘Imp-L2-/-, GR’ Imp-L2Def42/Imp-L2Def20, GR-57; ‘control’
(black bar) arm-Gal4, UAS-GFP. P-values were determined using unpaired Student’s t-test (n = 40, except for bars 1-3 in (c): bar 1, n = 31; bars 2
and 3, n = 17). Error bars represent s.d.
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dilp2-lacZIndeed, expression profiling revealed a slight
upregulation of Imp-L2 after 12 hours complete starvation
[27]. We could not detect a change in Imp-L2 protein
expression in the brain, the ring gland or the gut
after complete starvation for 24 hours (data not
shown). However, Imp-L2 was induced in fat body
cells, where it appeared in vesicle-like structures
(Figure 4d). Thus, under adverse nutritional
conditions,  Drosophila larvae weaken IIS by
upregulating Imp-L2 expression in the fat body.
D Di is sc cu us ss si io on n
IIS signaling has evolved in animals to regulate growth and
metabolism in accordance with environmental conditions.
Appropriate IIS activity is ensured at several levels, including
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Imp-L2 is necessary for blocking dInR signaling under starvation. ( (a a, ,b b) ) tGPH fluorescence (green, showing PIP3 levels and thus indicating IIS activity) in
the fat body of feeding third instar larvae under different nutritional conditions. Nuclear staining (Hoechst) is shown in blue in the right panels. (a)
Under normal conditions (‘yeast’), IIS activity is high in wild-type feeding third instar larvae. Upon starvation, only little PIP3 localizes to the
membranes of fat body cells. (b) In Imp-L2 mutants, IIS activity is higher than in control larvae and only slightly reduced after 4 h PBS starvation. ( (c c) )
Survival of Imp-L2Def42/Imp-L2Def20 early third instar larvae is severely compromised under starvation conditions. One copy of the genomic rescue
construct (GR) suffices to restore viability. Heterozygous larvae were Imp-L2Def42/+, control larvae y,w/w. Larvae (40) were subjected for 24 h to
20% glucose, 1% glucose or PBS. The experiment was repeated twice. ( (d d) ) In starved larvae (y, w), Imp-L2 protein expression (green) is induced in fat
body cells after 24 h PBS starvation. Imp-L2 is localized to vesicle-like structures but not detectable under normal nutritional conditions. Genotypes:
(a,d) y, w; (b) y, w; Imp-L2Def42/Imp-L2Def20.
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Hoechstthe controlled expression of binding partners of the
extracellular ligands. Surprisingly, the well-characterized
vertebrate IGFBPs have no obvious homologs in lower
organisms. Here, we used a genetic strategy to search for
negative regulators of IIS in Drosophila. Our approach led to
the identification of Imp-L2 as a functional insulin-binding
protein and antagonist of IIS.
Imp-L2 encodes a secreted peptide containing two Ig C2-like
domains. Consistent with its secretion, the effects of Imp-L2
overexpression are non-autonomous. Tissue-specific over-
expression of Imp-L2, for example in the larval fat body,
results in a systemic response, and the entire animal is
impaired in its capacity to grow. Conversely, the loss of Imp-
L2 function produces larger animals. Our analysis of IIS
activity (by means of the tGPH reporter in vivo) shows that
Imp-L2 functions to downregulate IIS. We further show that
wild-type Imp-L2 - but not a truncated version lacking the
second Ig C2-like domain - binds Dilp2, consistent with
previous findings that Imp-L2 binds human insulin, IGF-I,
IGF-II and proinsulin [22].
Thus, despite lacking any clear ortholog of the classical
IGFBPs with their characteristic amino-terminal IGFBP
motifs, invertebrates such as flies can regulate IIS activity at
the level of the ligands as a result of Imp-L2 expression.
Orthologs of Imp-L2 are present in C. elegans, Apis mellifera,
Anopheles gambiae,  Spodoptera frugiperda and  Drosophila
pseudoobscura. Importantly, the second Ig C2-like domain of
Imp-L2 also has sequence homology to the carboxyl
terminus of IGFBP-7, which is the only IGFBP that, besides
binding to IGFs, also binds insulin (although this binding
could not be detected in a different assay [7]). We speculate
that Imp-L2 resembles an ancestral insulin-binding protein
and that IGFBP-7 evolved from such an ancestor molecule
by replacing the amino-terminal Ig C2-like domain with the
IGFBP motif.
Interestingly, Dilp2 and Imp-L2 are found in a complex
with dALS (acid-labile subunit [28]). In vertebrates, most of
the circulating IGFs are part of ternary complexes consisting
of an IGF, IGFBP-3 and ALS [29]. These ternary complexes
prolong the half-lives of the IGFs and restrict them to the
vascular system, because the 150 kDa complexes cross the
capillary barrier very poorly. IGFs can also be found in
binary complexes of about 50 kDa with several IGFBP
species but there is only little (< 5%) free circulating IGF
[29]. Thus, it will be interesting to analyze the composition
and bioactivities of Dilp2/Imp-L2/ALS complexes in Drosophila.
IIS coordinates nutritional status with growth and
metabolism in developing Drosophila. It has been shown
that IIS regulates the storage of nutrients in the fat body
[24], an organ that resembles the mammalian liver as the
principal site of stored glycogen [30]. Even under adverse
nutritional conditions, fat body cells with increased IIS
activity continue stockpiling nutrients, thereby limiting the
amount of circulating nutrients, which induces hyper-
sensitivity to starvation of the larva [24]. Upon starvation,
the expression of dilp3 and  dilp5 is suppressed at the
transcriptional level in the m-NSCs [18]. Our study reveals
an additional layer of IIS regulation. Whereas Imp-L2 is not
expressed in the fat body of fed larvae, starved animals
induce  Imp-L2 expression in the fat body to systemically
dampen IIS activity. A lack of this control mechanism is
lethal under unfavorable nutritional conditions, as Imp-L2
mutant larvae fail to cope with starvation.
C Co on nc cl lu us si io on ns s
Our study provides the first functional characterization of
an insulin-binding protein in invertebrates. We have
identified Imp-L2 as a secreted antagonist of IIS in
Drosophila. Given the sequence homology of their Ig
domains, we propose that Imp-L2 is a functional homolog
of vertebrate IGFBP-7. Because both Imp-L2 and IGFBP-7
are potent inhibitors of growth and Imp-L2 is essential for
the endurance of periods of starvation, it is likely that the
original function of the insulin-binding molecules was to
keep IIS in check when nutrients were scarce. Thus, in
accordance with several reports suggesting that IGFBP-7 acts
as a tumor suppressor, loss of IGFBP-7 may provide tumor
cells with a growth advantage under conditions of local
nutrient deprivation, such as in prevascularized stages of
tumorigenesis.
M Ma at te er ri ia al ls s   a an nd d   m me et th ho od ds s
F Fl ly y   s st to oc ck ks s
The following fly stocks and transgenes have been used: y w;
w1118; arm-Gal4; Act5C-Gal4; UAS-GFP; UAS-lacZ (all from
the Bloomington Drosophila stock center); GMR-Gal4 (a gift
of M. Freeman); ppl-Gal4 (a gift of M. Pankratz); UAS-dInR
[17]; Df(3L)AC1 [17]; tGPH [24]; GMR>w+>Gal4 [17]; UAS-
dPTEN [31]; UAS-dilp2 [17]; GE24013 (GenExel). All
crosses were performed at 25°C unless stated otherwise.
E EP P   s sc cr re ee en n   a an nd d   i is so ol la at ti io on n   o of f   I Im mp p- -L L2 2 a al ll le el le es s
The EP screen that led to the identification of Imp-L2 will be
described elsewhere (F.W., W.B., H.S., D. Nellen, K. Basler
and E.H., unpublished work). A double-headed EP element
(containing ten Gal4-binding sites at each end) suppressing
the GMR-Gal4, UAS-InR big eye phenotype was identified in
the Imp-L2 locus. Plasmid rescue of EP5.66 revealed that it
was inserted 6,969 bp upstream of the first exon of the Imp-
L2-RB (CG15009-RB) transcript.
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an EMS mutagenesis screen in which we selected mutated
chromosomes carrying EP5.66 that could no longer
suppress the dInR overexpression phenotype in the eye.
EP5.66 males were fed with 25 mM EMS and subsequently
crossed to GMR-Gal4, UAS-dInR virgins. 39,000 F1 flies
were screened for a reversion of the suppressive effect of
EP5.66 on the growth phenotype caused by GMR-Gal4,
UAS-dInR. Only one of the identified reversion lines, Imp-
L2MG2, could be confirmed. Sequencing the genomic DNA
of Imp-L2MG2 revealed a point mutation that resulted in a
truncation (Trp232Stop).
In order to generate additional Imp-L2 mutants, the P-
element GE24013 (marked with white+) inserted 102 bp
upstream of the first exon of the Imp-L2-RC transcript was
mobilized by supplying ∆2-3 transposase. Jump starter
males were mated with balancer females, and single F1 w-
males were recrossed to balancer virgins. Stocks (350) were
established and molecularly tested for deletions by single-
fly PCR using several primer pairs, leading to the identifi-
cation of the alleles Imp-L2Def42,  Imp-L2Def20,  Imp-L2Def35,
Imp-L2Def223 and Imp-L2Def29.
C Co on ns st tr ru uc ct ti io on n   o of f   p pl la as sm mi id ds s
In order to generate the UAS-Imp-L2 construct, a BglII/XhoI
fragment of Imp-L2 was excised from the Imp-L2-RB
containing cDNA clone LP06542 and inserted into pUAST
[32]. To obtain UAS-s.Imp-L2, the second and third exons of
Imp-L2 were amplified by PCR from genomic DNA. The
fragment was subcloned into pCRII-Topo (Invitrogen). The
insert was then excised with EcoRI and cloned into pUAST
[32]. Because of the lack of the first exon of the Imp-L2-RB
transcript (containing three upstream open reading frames),
UAS-s.Imp-L2 has a stronger phenotype than UAS-Imp-L2.
The EP element contains ten UAS sites, whereas the UAS
transgenes contain only five.
For the generation of the genomic rescue construct, the
genomic fragment L2G314 (kindly provided by J. Natzle)
was used. The fragment (5 kb of genomic sequence
upstream of the first exon of the Imp-L2-RB transcript and
1 kb downstream of the third exon) was excised with
BamHI and Asp718 and inserted into the pCaSpeR-4 trans-
formation vector [33].
The  Flag-dilp2 construct was created by PCR
amplification of the dilp2 coding sequence without the
signal peptide sequence from the full-length cDNA clone,
EST GH11579 (obtained from Research Genetics). The
resulting PCR product was then equipped with the
hemagglutinin signal peptide sequence and a Flag tag
and inserted into pUAST [32].
C Ce el ll l   c cu ul lt tu ur re e
Drosophila embryonic S2 cells were grown at 25°C in
Schneider’s Drosophila medium (Gibco/Invitrogen) supple-
mented with 10% heat-inactivated fetal-calf serum (FCS),
penicillin and streptomycin.
For the construction of the stably expressing Flag-dilp2 cell
line, S2 cells were co-transfected with UAS-Flag-dilp2, Act-
Gal4 and a third vector containing a blasticidin-resistance
gene, using effectene transfection reagent (Qiagen). Two
days after the transfection, the selection medium (Schneider’s
containing 10% FCS and 25 µg/ml blasticidin) was added
to the cells. After 10 days the selection medium was replaced
by Schneider’s containing 10% FCS and 10 µg/ml blasticidin.
I In n   v vi it tr ro o p pu ul ll ld do ow wn n   a as ss sa ay y
S2 cells expressing Flag-dilp2 were grown to confluence in
175 cm2 culture flasks, washed with ice-cold PBS and
extracted in immunopreciptiation (IP) buffer (120 mM
NaCl, 50 mM Tris pH 7.5, 20 mM NaF, 1 mM benzamidine,
1 mM EDTA, 6 mM EGTA, 15 mM Na4P2O7, 0.5% Nonidet
P-40, 30 mM β-glycerolphosphate, 1x Complete Mini
protease inhibitor (Roche)). After incubation for 15 min on
an orbital shaker at 4°C, solubilized material was recovered
by centrifugation at 13,000 rpm for 15 min and super-
natants were collected. Anti-Flag antibody (5 µg, Sigma M2,
F3165) was added and incubated over night at 4°C while
rotating. Protein G sepharose beads (Amersham Biosciences)
were added for 2 h and the beads were washed four times
with IP buffer. Cell lysate from native S2 cells was subjected
to the same procedure and the resulting beads were used as
control. To verify the immunoprecipitation, a fraction of the
beads was incubated with SDS loading buffer (62.5 mM
Tris-HCl pH 6.8, 20 mM DTT, 2% SDS, 25% glycerol, 0.02%
bromophenol blue) for 5 min at 90°C and the proteins
were separated by SDS-PAGE. The presence of Flag-Dilp2
was confirmed by immunoblotting.
For the in vitro translation the Imp-L2-RC cDNA (SD23735)
was cloned into pCRII.1 (Invitrogen) downstream of the
SP6 polymerase promoter. As a control, the point mutation
encoding a non-functional, truncated version of Imp-L2
(identified in the EMS reversion mutagenesis) was inserted
into  Imp-L2-RC (in pCRII.1 see above) using the Quick-
Change site-directed mutagenesis protocol (Stratagene).
Both the Imp-L2 and the Imp-L2MG2 constructs were trans-
lated in vitro using the TNT Quick coupled transcription/
translation system (Promega) according to the manu-
facturer’s protocol. Briefly, 2 µg of DNA was incubated with
20 µCi [35S]methionine and 20 µl TNT Quick Master Mix in
a total volume of 25 µl for 90 min at 30°C. The product
(2.5 µl) was used in the in vitro pulldown assay together
with Flag-Dilp2 bound to beads or with control beads in IP
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overnight at 4°C, the beads were washed six times with IP
buffer (0.05% NP-40) and incubated with SDS loading
buffer containing 100 mM DTT for 10 min at 80°C. The
dissociated proteins were separated using SDS-PAGE and
detected by autoradiography.
P Ph he en no ot ty yp pi ic c   a an na al ly ys se es s
Freshly eclosed flies were collected, separated according to
sex, placed on normal fly food for 3 days and anesthetized
for 1 min with ether before weighing. Weight was deter-
mined using a Mettler Toledo MX5 microbalance. Wing size
was analyzed as described [34]. ImageJ 1.32j software was
used to determine the pixels of the wing area. Scanning
electron microscope pictures were taken from adult flies
that were critical-point dried and coated with gold.
Heat-shock induced overexpression clones (y,  w, hs-Flp;
GMR>w+>Gal4) were induced 24-48 h after egg-laying by a
1 h heat shock at 37°C. Tangential sections of adult eyes
were generated as described [35].
S St ta ar rv va at ti io on n   e ex xp pe er ri im me en nt ts s
For all starvation experiments, eggs were collected for 2 h on
apple agar plates supplemented with yeast. After 72 h,
larvae were quickly washed in PBS and transferred either to
a new apple agar plate with yeast (normal food, called
‘yeast’ henceforth), a solution containing 20% glucose in
PBS, or a filter paper soaked with 1% glucose in PBS or PBS
only. After 24 h, dead larvae were counted.
For the tGPH reporter analysis under starvation, the ‘PBS’ or
‘yeast’ conditions were used (see above). After 4 h starva-
tion, larvae were dissected in PBS, fixed and stained with
Hoechst. Pictures were taken using a Leica SP2 confocal
laser scanning microscope.
I Im mm mu un no oh hi is st to oc ch he em mi is st tr ry y   a an nd d   i in n   s si it tu u   h hy yb br ri id di iz za at ti io on n
The antibody against Imp-L2 was described earlier [25] and
kindly provided by J. Natzle (Department of Molecular and
Cellular Biology, University of California, Davis, USA).
Antibody staining against Imp-L2 was performed using the
following dilutions: rat anti-Imp-L2 (1:500), donkey anti-
rat-FITC (1:200, Jackson). Other antibodies used were: anti-
β-galactosidase (1:2,000, polyclonal, rabbit), an antibody
against the carboxyl terminus of dInR (INRcT, 1:10,000)
[36]. Nuclei were either stained with 4’,6-diamidino-2-
phenylindole (DAPI) or Hoechst. Pictures were taken using
a Leica SP2 confocal laser scanning microscope.
RNA in situ hybridization using digoxigenin-labeled probes
was performed as described [17]. The probes against Imp-L2
were derived from s.Imp-L2 in a pBluescript SK+ vector.
A Ac ck kn no ow wl le ed dg ge em me en nt ts s
We thank P. Léopold for openly communicating results before publica-
tion, J. Natzle for the Imp-L2 antibody and the plasmid used for the
genomic rescue construct, Ch. Hugentobler, A. Baer, A. Straessle, P. Gast
and B. Bruehlmann for technical support, J. Reiling for critical reading of
the manuscript, E. Brunner and the members of the Hafen lab for helpful
discussions and valuable suggestions, and GenExel and the Bloomington
stock center for fly stocks. This work was supported by grants from the
Swiss National Science Foundation and the Kanton of Zürich.
A Ad dd di it ti io on na al l   d da at ta a   f fi il le es s
The following file is available: Additional data file 1
contains three figures. Figure S1 shows that the over-
expression of Imp-L2 results in reduced PIP3 levels in vivo. In
Figure S2, the dynamic expression pattern of Imp-L2 during
development is shown. Figure S3 demonstrates that a
reduction in Dilp levels enhances the growth-inhibitory
effect of Imp-L2.
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